IL17A and Hepatic fibrosis: Pharmacological or genetic inhibition of IL-17 production or its signaling pathway (Il17a-/- or Il17ra-/- mice, respectively) in various liver fibrosis models led to reduced HSC activation and limited liver fibrosis progression (103, 111, 141).